These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 7655028)

  • 41. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice.
    Eybl V; Kotyzová D; Kolek M; Koutenský J; Nielsen P
    Toxicol Lett; 2002 Mar; 128(1-3):169-75. PubMed ID: 11869827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Salivary measurement of deferiprone concentrations and correlation with serum levels.
    Pope E; Berkovitch M; Klein J; Fassos F; Koren G
    Ther Drug Monit; 1997 Feb; 19(1):95-7. PubMed ID: 9029756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
    Emara AM; El Kelany RS; Moustafa KA
    Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract]   [Full Text] [Related]  

  • 46. Increased susceptibility of the sickle cell membrane Ca2+ + Mg(2+)-ATPase to t-butylhydroperoxide: protective effects of ascorbate and desferal.
    Moore RB; Hulgan TM; Green JW; Jenkins LD
    Blood; 1992 Mar; 79(5):1334-41. PubMed ID: 1531618
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
    Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
    al-Refaie FN; Wickens DG; Wonke B; Kontoghiorghes GJ; Hoffbrand AV
    Br J Haematol; 1992 Oct; 82(2):431-6. PubMed ID: 1419825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oxidative denaturation of red blood cells in thalassemia.
    Shinar E; Rachmilewitz EA
    Semin Hematol; 1990 Jan; 27(1):70-82. PubMed ID: 2405497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
    Schmidt PJ; Racie T; Westerman M; Fitzgerald K; Butler JS; Fleming MD
    Am J Hematol; 2015 Apr; 90(4):310-3. PubMed ID: 25557851
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia.
    Olivieri NF; Koren G; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM
    Blood; 1992 May; 79(10):2741-8. PubMed ID: 1586721
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
    Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
    Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES; Karasmanis K; Perifanis V; Vlachaki E; Tziomalos K; Economou M
    Hemoglobin; 2014; 38(2):111-4. PubMed ID: 24351163
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major.
    Gomber S; Dabas A; Bagmar S; Madhu SV
    J Pediatr Hematol Oncol; 2018 Jan; 40(1):56-59. PubMed ID: 29200160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antioxidant defense status of red blood cells of patients with beta-thalassemia and Ebeta-thalassemia.
    Chakraborty D; Bhattacharyya M
    Clin Chim Acta; 2001 Mar; 305(1-2):123-9. PubMed ID: 11249931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.